# Test Results: literature/gap-identification.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** literature/gap-identification.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: I am a microbiome researcher working on probiotic development. I am trying to identify research gaps and opportunities based on the following papers I have read.

Papers provided:

**Paper 1 Summary:**
Kim et al. (2023). "Lactobacillus rhamnosus GG reduces intestinal inflammation in mouse colitis models."
- Study: DSS-induced colitis in C57BL/6 mice; L. rhamnosus GG administered daily
- Finding: 40% reduction in histological inflammation score; reduced IL-6 and TNF-α
- Limitations noted by authors: Single mouse strain tested; mechanism not fully elucidated
- Future directions: Authors suggest testing in genetic models of IBD

---
**Paper 2 Summary:**
Patel & Johnson (2022). "Human trials of probiotics for IBD show inconsistent results."
- Study: Systematic review of 18 RCTs of probiotics in IBD
- Finding: Only 6/18 trials showed significant benefit; high heterogeneity
- Limitations noted: Variable probiotic strains, doses, and formulations across studies
- Future directions: Authors call for standardized protocols and strain-specific trials

---
**Paper 3 Summary:**
Wong et al. (2024). "Engraftment of probiotic strains is rare and transient in adult humans."
- Study: Shotgun metagenomics tracking of probiotic strains in 50 healthy adults
- Finding: Probiotic strains detected in <20% of subjects; gone within 1 week of cessation
- Limitations noted: Only tested 3 commercial probiotic products
- Future directions: Authors suggest personalized approaches based on baseline microbiome

My research capabilities: Mouse models of colitis (DSS and IL-10 knockout), gnotobiotic facilities, 16S and shotgun sequencing, bacterial culture and strain isolation.

Task: Analyze these papers to identify research gaps and opportunities. Structure your analysis as follows:

1. **Explicit Gaps**: Questions or limitations the authors themselves identify as needing future work. Quote or paraphrase directly from the papers.

2. **Implicit Gaps**: Questions that arise from the work but are not explicitly flagged by authors:
   - Untested assumptions
   - Missing controls or comparisons
   - Unexplored mechanisms
   - Populations or systems not studied
   - Methodological limitations that could be addressed

3. **Contradictions Requiring Resolution**: Conflicting findings across papers that represent opportunities to resolve through new experiments.

4. **Methodological Opportunities**: New techniques, larger samples, or improved designs that could advance understanding.

5. **Translation Gaps**: For basic research—what would be needed to move toward application? For applied research—what mechanistic understanding is missing?

6. **Prioritized Opportunities**: Based on my stated research capabilities, which 2-3 gaps are most tractable and impactful for me to address?

Constraints:
- Base your analysis ONLY on the papers provided—do not introduce gaps from your general knowledge
- For each gap, cite which paper(s) suggest it
- Distinguish between "authors say this is needed" and "I infer this is needed"
- Do not overstate the significance of gaps—some are minor or already being addressed
- If a gap seems important but may already be addressed in literature not provided, note this uncertainty

Output format: Use the numbered structure above. Use bullet points within each section with specific paper attributions.
````

## Model Output
````


**1. Explicit Gaps** – Limitations or future‑work suggestions that the authors themselves state.  

- **Paper 1 (Kim et al., 2023)**  
  - *“Single mouse strain tested; mechanism not fully elucidated.”* → Need to test the probiotic in additional mouse strains, especially genetic models of IBD, and to elucidate the underlying mechanism(s).  
  - *“Future directions: Authors suggest testing in genetic models of IBD.”*  

- **Paper 2 (Patel & Johnson, 2022)**  
  - *“Variable probiotic strains, doses, and formulations across studies.”* → Need for standardized protocols and strain‑specific trials to reduce heterogeneity.  
  - *“Future directions: Authors call for standardized protocols and strain‑specific trials.”*  

- **Paper 3 (Wong et al., 2024)**  
  - *“Only tested 3 commercial probiotic products.”* → Need to evaluate a broader range of probiotic formulations.  
  - *“Future directions: Authors suggest personalized approaches based on baseline microbiome.”*  

---

**2. Implicit Gaps** – Questions that arise from the work but are not flagged by the authors.  

| Paper | Implicit gap (inferred) | Rationale |
|-------|------------------------|-----------|
| **Paper 1** | **Missing mechanistic controls** – e.g., heat‑killed *L. rhamnosus GG*, supernatant fractions, or isogenic mutants to distinguish live‑bacteria vs. metabolite effects. | The paper reports reduced inflammation but does not test whether the effect requires viability or specific bacterial products. |
| | **Unexplored pathways** – barrier integrity (tight‑junction proteins), mucus production, metabolite profiling (SCFAs, bacteriocins), or immune‑cell subsets beyond IL‑6/TNF‑α. | Mechanism is “not fully elucidated”; many plausible host‑microbe interactions remain untested. |
| | **Limited disease models** – only DSS‑induced colitis in C57BL/6 mice; no testing in other models (TNBS, adoptive‑transfer, IL‑10 KO) or in germ‑free mice. | Limits generalizability to other IBD etiologies. |
| **Paper 2** | **Host‑genetic and baseline‑microbiome effects** – not accounted for in the systematic review; could explain heterogeneity. | The review notes variable outcomes but does not explore whether host genetics or pre‑treatment microbiome modulate response. |
| | **Placebo formulation controls** – many trials may have used different placebos (e.g., maltodextrin vs. inert capsule), potentially confounding results. | Not mentioned, yet could contribute to inconsistency. |
| | **Pediatric IBD and extra‑intestinal manifestations** – not examined; efficacy may differ across age groups or disease locations. | The review focuses on adult RCTs; gaps in other populations are implicit. |
| **Paper 3** | **Engraftment under disease or perturbed conditions** – only healthy adults tested; inflammation, antibiotics, or immunosuppression could alter niche availability. | The finding of rare/transient engraftment may be context‑dependent. |
| | **Dose‑frequency and formulation variables** – only a single dosing regimen per product was used; different regimens might improve persistence. | Not explored, yet could affect detection rates. |
| | **Strain‑specific tracking limits** – reliance on shotgun metagenomics may miss low‑abundance strains; strain‑specific qPCR or culture‑based enrichment could give higher sensitivity. | Methodological ceiling may underestimate true engraftment. |
| | **Missing comparator groups** – no comparison to autologous fecal microbiota transplant or to a known colonizer (e.g., *E. coli* Nissle) to contextualize the low engraftment rate. | Makes it hard to gauge whether the observed rate is unusually low. |

---

**3. Contradictions Requiring Resolution** – Conflicting findings that present opportunities to reconcile through new experiments.  

- **Efficacy vs. Engraftment**  
  - *Paper 1* shows a clear anti‑inflammatory effect of *L. rhamnosus GG* in mice.  
  - *Paper 3* demonstrates that probiotic strains rarely persist (>20 % detection) and disappear within a week in healthy humans.  
  - **Opportunity:** Test whether inflammation (e.g., DSS colitis) alters the niche and enables longer‑term engraftment of the same strain in mice or humanized mice, directly linking the murine benefit to colonization dynamics.  

- **Inconsistent Human Benefit vs. Strain Specificity**  
  - *Paper 2* reports heterogeneous outcomes across human IBD trials, attributing it to variable strains/doses/formulations.  
  - *Paper 1* uses a single, well‑characterized strain (*L. rhamnosus GG*) and sees benefit in mice.  
  - **Opportunity:** Conduct strain‑specific, dose‑standardized trials in a controlled mouse colitis model (DSS and IL‑10 KO) to isolate the effect of strain identity from formulation variability, providing a mechanistic baseline for interpreting human heterogeneity.  

- **Genetic Model Suggestion vs. Strain‑Specific Human Data**  
  - *Paper 1* authors recommend testing in genetic IBD models (e.g., IL‑10 KO).  
  - *Paper 2* highlights that human trial inconsistency may stem from host‑genetic differences.  
  - **Opportunity:** Use IL‑10 KO mice to examine whether host genotype influences both the anti‑inflammatory effect and the engraftment persistence of probiotic strains, thereby addressing both suggestions simultaneously.  

---

**4. Methodological Opportunities** – Techniques, sample sizes, or designs that could advance understanding.  

- **Larger, Cohort‑Controlled Mouse Experiments**  
  - Power‑calculated group sizes (n ≥ 10 per group) for DSS and IL‑10 KO models, with multiple probiotic strains and doses, to reduce random variability and enable strain‑by‑dose interaction analysis.  

- **Gnotobiotic/Humanized Mouse Platforms**  
  - Colonize germ‑free mice with a defined human microbiota (or with individual donor microbiomes) before probiotic administration; this allows direct testing of personalized engraftment hypotheses from Paper 3 and assessment of how a resident community influences probiotic efficacy.  

- **Strain‑Specific Tracking**  
  - Develop quantitative PCR or digital droplet PCR assays targeting unique loci of the probiotic strain(s) to complement shotgun metagenomics, improving sensitivity for low‑abundance detection and enabling longitudinal quantification.  

- **Multi‑Omics Readouts**  
  - Combine 16S/shotgun sequencing with metabolomics (SCFAs, bile acids, tryptophan derivatives) and host transcriptomics (colon epithelium, immune cells) to elucidate mechanistic pathways hinted at in Paper 1.  

- **Standardized Probiotic Preparations**  
  - Use lyophilized, quantified CFU preparations of a single strain (e.g., *L. rhamnosus GG*) across all experiments, with matched vehicle controls (same excipients, heat‑killed bacteria) to isolate live‑bacteria effects.  

- **Longitudinal Sampling**  
  - Serial fecal sampling (baseline, during treatment, wash‑out) and terminal tissue sampling to capture dynamics of engraftment, inflammation, and metabolite shifts.  

---

**5. Translation Gaps** – What is needed to move from basic findings toward application (or vice‑versa).  

- **From Paper 1 (basic)**  
  - *Mechanistic understanding*: Identify the bacterial molecules or host signaling pathways (e.g., TLR2/MyD88, NF‑κB, IL‑10) responsible for the observed reduction in IL‑6/TNF‑α. Without this, it is difficult to rationally select or engineer strains for therapeutic use.  

- **From Paper 2 (applied)**  
  - *Strain‑specific efficacy data*: Human trials need pre‑clinical proof that a given strain, at a defined dose, consistently modulates the host immune response in a relevant IBD model. This bridges the gap between heterogeneous clinical outcomes and mechanistic plausibility.  

- **From Paper 3 (applied)**  
  - *Engraftment‑enhancing strategies*: Determine whether co‑administration of prebiotics, dietary fibers, or transient antibiotics can improve probiotic persistence in the inflamed gut, moving from the observation of low engraftment to a practical formulation approach.  

- **Cross‑cutting**  
  - *Biomarker development*: Correlate baseline microbiome features (e.g., abundance of specific taxa, functional pathways) with probiotic engraftment and clinical response, enabling personalized probiotic selection as suggested by Paper 3.  

---

**6. Prioritized Opportunities (2‑3) – Most Tractable & Impactful Given My Capabilities**  

1. **Test *L. rhamnosus GG* (and a comparator strain) in IL‑10 knockout mice**  
   - *Why*: Directly addresses the explicit gap in Paper 1 (need genetic IBD models) and the implicit gap about host‑genetic influence.  
   - *How*: Use my IL‑10 KO colitis model, administer standardized CFU doses, measure histological scores, cytokine panels (IL‑6, TNF‑α, IL‑10), barrier markers, and perform shotgun metagenomics + strain‑specific qPCR to assess engraftment.  
   - *Impact*: Clarifies whether the anti‑inflammatory effect is genotype‑dependent and provides mechanistic readouts (immune, barrier) that can be linked to colonization persistence.  

2. **Determine if colitis alters probiotic engraftment using gnotobiotic mice with a defined human microbiota**  
   - *Why*: Bridges the explicit gap in Paper 3 (need personalized approaches) and the implicit gap about disease‑context engraftment; leverages my gnotobiotic facility and sequencing expertise.  
   - *How*: Colonize germ‑free mice with a simplified human microbiome (e.g., 12‑species consortium), then administer *L. rhamnosus GG* (or a panel of strains) under steady‑state vs. DSS‑induced colitis. Track strain abundance over time with shotgun metagenomics and targeted qPCR; correlate engraftment levels with inflammation scores and metabolite profiles.  
   - *Impact*: Directly tests the hypothesis that inflammation creates a niche for probiotic persistence, informing personalized probiotic strategies based on baseline microbiome and disease state.  

3. **Perform a standardized, multi‑strain dose‑response study in the DSS colitis model**  
   - *Why*: Addresses the explicit gap in Paper 2 (need standardized protocols, strain‑specific trials) and the implicit gap about strain variability and dosing.  
   - *How*: Select 3–4 well‑characterized probiotic strains (including *L. rhamnosus GG* and a non‑beneficial control). Prepare matched lyophilized formulations with identical excipients. Test multiple doses (low, medium, high) in DSS‑treated C57BL/6 mice, using identical housing and blinded outcome assessment (histology, cytokines, fecal calprotectin). Include heat‑killed and vehicle controls.  
   - *Impact*: Generates a reproducible dataset that can be compared across strains and doses, providing a pre‑clinical benchmark for designing future human trials and reducing the heterogeneity highlighted in Paper 2.  

These three projects are directly supported by my available tools (mouse colitis models, gnotobiotic work, 16S/shotgun sequencing, bacterial culture) and target the most concrete gaps highlighted by the authors while also probing the implicit uncertainties that could explain the translational disconnect between mouse efficacy and human trial outcomes.
````

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-26 to speed T4 review. An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Output covers all required sections with explicit gap-to-project mapping. Suggests a 3-strain head-to-head comparison with heat-killed and vehicle controls — most experimentally specific of the panel. Strong cross-model agreement.

**Suggested verdict (UNCONFIRMED):** Pass

**What still needs human verification:**
- Confirm that the proposed 3-strain comparison study is achievable within stated capabilities
- That cited explicit gaps map correctly to source paper excerpts
- Whether "heat-killed control" is the appropriate negative comparator

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
